Vera Therapeutics stockholders approve routine annual meeting matters, elect directors

Filed May 26, 2026 · Period ending May 21, 2026 · ~1 min read

Key Changes

• low

  Stockholders elected three Class II directors to serve three-year terms through 2029: Michael Morrisey, Patrick Enright, and James Meyers. Meyers received strongest support while Morrisey had most withheld votes at 13.8 million.

  Item 5.07 verify on EDGAR →
• low

  KPMG LLP ratified as independent auditor for fiscal 2026 with overwhelming support (61.8 million for vs 44,710 against).

  Item 5.07 verify on EDGAR →
• low

  Executive compensation approved on advisory basis with 56.6 million votes for versus 2.4 million against, indicating general shareholder support for management pay structure.

  Item 5.07 verify on EDGAR →